"GSK tells investors: Luke is a highly respected, experienced global biopharma leader, having worked at senior levels in the US, Europe and Asia, at AstraZeneca, Roche and Sanofi-Aventis, prior to joining GSK. This experience, and significant contribution to GSK, mean he is exceptionally well-qualified to lead the company, and to deliver the patient and shareholder value inherent in the company's future ambitions."
"The first ever female CEO of a major pharmaceutical company, Dame Emma Walmsley, is set to hand over GSK's reins on New Year's Day 2026. One of her key achievements was the demerger of Haleon, the company behind consumer health brands such as Beechams. That not just strengthened GSK's balance sheet but also sharpened the group's focus on speciality medicines and vaccines. There's an exciting pipeline ahead and, this year alone, GSK's on track for five major regulatory approvals."
GSK will replace Emma Walmsley as chief executive after nine years, with Luke Miels named CEO Designate and due to take the role on 1 January 2026. Miels is currently chief commercial officer and has held senior biopharma roles in the US, Europe and Asia at AstraZeneca, Roche and Sanofi-Aventis. The Board considered internal and external candidates and appointed Miels following long-term succession planning. Walmsley led a wide-ranging overhaul, including spinning off the consumer health business into Haleon. GSK has a strengthened balance sheet, a focus on speciality medicines and vaccines, and a pipeline targeting multiple regulatory approvals.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]